Related Experiment Video

Updated: Jun 11, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities

Mark Boguniewicz1,2, Lawrence D Sher3, Amy S Paller4

  • 1Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.

Journal of Asthma and Allergy
|June 10, 2026
PubMed

Insights

Dupilumab effectively treats moderate-to-severe atopic dermatitis (AD) in young children. This injectable medication improved skin condition regardless of co-existing conditions like asthma or allergies.

Area of Science:

  • Pediatric Dermatology
  • Allergology
  • Immunodermatology

Background:

  • Atopic dermatitis (AD) is a common chronic inflammatory skin condition in infants and children.
  • Co-existing allergic conditions such as asthma, allergic rhinitis, and food allergy frequently accompany AD.
  • Limited data existed on the efficacy of specific treatments in pediatric populations with comorbid allergic diseases.

Purpose of the Study:

  • To evaluate the efficacy of dupilumab in treating moderate-to-severe atopic dermatitis in infants and children.
  • To assess whether the presence of asthma, allergic rhinitis, or food allergy impacts dupilumab's effectiveness in this age group.

Main Methods:

  • Post hoc analysis of the LIBERTY AD PRESCHOOL trial (NCT03346434).
  • Included 162 infants and children aged 6 months to 5 years with moderate-to-severe AD.
  • Assessed AD improvement in patients with and without comorbid allergic conditions.

Main Results:

  • Dupilumab demonstrated significant improvement in atopic dermatitis.
  • Efficacy of dupilumab was consistent across participants, irrespective of the presence of asthma, allergic rhinitis, or food allergy.
  • The safety profile of dupilumab was consistent with previously established data.

Conclusions:

  • Dupilumab is an effective treatment option for moderate-to-severe atopic dermatitis in infants and children.
  • The medication's benefits for AD are not diminished by the presence of common allergic comorbidities.
  • Dupilumab offers a well-tolerated therapeutic choice for this pediatric population.
Abstract

Keywords:
Allergic rhinitisAsthmaAtopic dermatitisDupilumab

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...